Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ABL1 | P00519 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PKM | P14618 | 1/20 | 0.77 |
| ▸ | IDE | P14735 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | HLCS | P50747 | 6/20 | 0.69 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17348120 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12852783 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL18413943 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13380511 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13563116 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13525124 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14594154 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL6751270 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL12119296 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL13525109 | 1.00 | TDP1 (0.77) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11840543-B2 | Compounds and uses | THE UNIVERSITY OF QUEENSLAND (AU) | 2023-12-12 | — | — | US | disclosed |
| WO-2023232829-A1 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING | ILLUMINA, INC (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11795492-B2 | Methods of nucleic acid sample preparation | ArcherDX, LLC. (US) | 2023-10-24 | — | — | US | disclosed |
| WO-2023186815-A1 | LABELED AVIDIN AND METHODS FOR SEQUENCING | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | WO | disclosed |
| US-20230285464-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3159352-B1 | STITCHED POLYPEPTIDES | HARVARD COLLEGE (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-11672828-B2 | Cellular receptors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-06-13 | — | — | US | disclosed |
| US-20230176063-A1 | PHOTOREACTIVE AND CLEAVABLE PROBES FOR TAGGING BIOMOLECULES | ACADEMIA SINICA (TW) | 2023-06-08 | — | — | US | disclosed |
| US-8298513-B2 | Hexatriene-β-carbonyl compound | OSAKA UNIVERSITY (JP) | 2012-10-30 | — | — | US | disclosed |
| EP-2508531-A1 | Stitched polypeptides | President and Fellows of Harvard College (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20110321183-A1 | METHODS FOR LIGATION AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2011153817-A1 | CYCLOPEPTIDES USED AS MELANOCORTIN-4 RECEPTOR AGONIST | 中国人民解放军军事医学科学院毒物药物研究所 (CN) | 2011-12-15 | — | — | WO | disclosed |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
| US-20100184645-A1 | STITCHED POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-07-22 | — | — | US | disclosed |
| US-20100075922-A1 | HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF | SANOFI-AVENTIS (FR) | 2010-03-25 | — | — | US | disclosed |
| WO-2010024930-A2 | CORTISTATIN ANALOGUES AND SYNTHESES THEROF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | OSAKA UNIVERSITY (JP) | 2010-01-14 | — | — | US | disclosed |
| WO-2008121767-A2 | STITCHED POLYPEPTIDES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | TDP1 104/4885MEN1 4172/4885ABL1 4327/4885 |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | PTMS, CHAMP1, RAB5IF | TDP1 2771/4885MEN1 4213/4885ABL1 4402/4885 |
| US-20100184645-A1 | STITCHED POLYPEPTIDES | VIP, IAPP, NGLY1 | TDP1 2051/4885MEN1 1278/4885ABL1 865/4885 |
| US-11672828-B2 | Cellular receptors and uses thereof | SRPRA, NPBWR1, BCAP31 | TDP1 3462/4885MEN1 3868/4885ABL1 4348/4885 |
| US-20100075922-A1 | HEPARINS INCLUDING AT LEAST ONE COVALENT BOND WITH BIOTIN OR A BIOTIN DERIVATIVE, METHOD FOR PREPARING SAME AND USE THEREOF | BTD, HBB, HLCS | TDP1 4647/4885MEN1 1640/4885ABL1 4284/4885 |
| US-11840543-B2 | Compounds and uses | NLRP3, NOD1, IAPP | TDP1 2226/4885MEN1 1725/4885ABL1 4322/4885 |
| US-20100008857-A1 | NOVEL HEXATRIENE-BETA-CARBONYL COMPOUND | CBR1, CBR3, DCXR | TDP1 4770/4885MEN1 4487/4885ABL1 4163/4885 |
| US-20230285464-A1 | NOVEL CELLULAR RECEPTORS AND USES THEREOF | SRPRA, CACYBP, SRPRB | TDP1 3400/4885MEN1 4246/4885ABL1 4564/4885 |
| US-20110321183-A1 | METHODS FOR LIGATION AND USES THEREOF | ACOT7, LYPLA1, ACSL3 | TDP1 1417/4885MEN1 2222/4885ABL1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.